Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,513
  • Shares Outstanding, K 16,683
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,740 K
  • 60-Month Beta 1.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.51
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.20
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +24.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.69 +17.36%
on 11/14/19
1.13 -28.32%
on 11/11/19
-0.04 (-4.36%)
since 11/06/19
3-Month
0.69 +17.36%
on 11/14/19
1.13 -28.32%
on 11/11/19
+0.01 (+0.75%)
since 09/06/19
52-Week
0.60 +35.00%
on 12/27/18
3.25 -75.08%
on 03/18/19
-0.17 (-17.35%)
since 12/06/18

Most Recent Stories

More News
Dare Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc. As...

DARE : 0.81 (unch)
ANIK : 57.48 (+0.75%)
STIM : 4.59 (+1.10%)
Dare Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update.

DARE : 0.81 (unch)
Dare Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene(R) Hormone-Free Contraceptive Candidate

-- Currently marketed contraceptives with similar results in their PCT clinical studies subsequently demonstrated 6-month "typical use" effectiveness of 86-91% in their pivotal clinical trials, in the...

DARE : 0.81 (unch)
Dare Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc. Dare entered into the agreement...

DARE : 0.81 (unch)
Dare Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2019,...

DARE : 0.81 (unch)
Dare Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical...

DARE : 0.81 (unch)
Dare Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a...

DARE : 0.81 (unch)
Dare Bioscience to Participate in Two Upcoming Investor Conferences

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:...

DARE : 0.81 (unch)
Dare Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo,...

DARE : 0.81 (unch)
Dare Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th annual Partnership Opportunities...

DARE : 0.81 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade DARE with:

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

2nd Resistance Point 0.86
1st Resistance Point 0.83
Last Price 0.81
1st Support Level 0.79
2nd Support Level 0.78

See More

52-Week High 3.25
Fibonacci 61.8% 2.24
Fibonacci 50% 1.92
Fibonacci 38.2% 1.61
Last Price 0.81
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar